These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro antiviral activity of distamycin A against clinical isolates of herpes simplex virus 1 and 2 from transplanted patients.
    Author: Matteoli B, Bernardini S, Iuliano R, Parenti S, Freer G, Broccolo F, Baggiani A, Subissi A, Arcamone F, Ceccherini-Nelli L.
    Journal: Intervirology; 2008; 51(3):166-72. PubMed ID: 18663321.
    Abstract:
    OBJECTIVE(S): Herpes simplex virus (HSV) infections in immunocompromised individuals may require prolonged antiviral therapy resulting in the emergence of viral strains resistant to the currently employed antiviral drugs. Distamycin A (DA), a basic antibiotic belonging to the lexitropsin DNA minor groove binding drugs, exhibits antiviral properties. In this study we evaluated the in vitro cytotoxicity and antiviral activity of DA against HSV type 1 and HSV type 2 clinical isolates from transplanted patients and compared them with those of acyclovir (ACV) in search of alternative antiviral drugs. METHODS: Viral detection and typing was performed by multiplex PCR and immunofluorescence assay; the in vitro cytotoxicity of DA and the antiviral activity of ACV and DA was evaluated respectively by neutral red uptake assay and plaque reduction assay for HSV2 isolates and fluorescence reduction assay for HSV1 isolates. RESULTS: Tissue culture 50% cytotoxic concentration of DA was 58 muM. Tissue culture 50% inhibitory concentration values ranged from 0.16 to 7.4 muM for the ACV-sensitive and from 5.4 to 32 muM for the ACV-resistant viral strains. CONCLUSIONS: In spite of the lower activity against ACV-resistant strains, DA may be used as an antiherpetic drug.
    [Abstract] [Full Text] [Related] [New Search]